Trials / Terminated
TerminatedNCT02214706
Treatment of Port Wine Stains Using Pulsed Dye Laser, Erbium Yag Laser and Topical Sirolimus
Treatment of Port Wine Stains Using Pulsed Dye Laser, Erbium Yag Laser and Topical Sirolimus in an Open Label Pilot Study (POLAR).
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Erasmus Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to improve the therapeutic outcome of laser therapy for port wine stains by using a combination treatment of the pulsed dye laser (PDL), erbium yag laser and topical sirolimus.
Detailed description
In the first treatment period all patients will receive a total of five treatments with two week intervals. Every patient will receive the following four treatments (utilizing a template with separate squares of 1cm2): 1) PDL treatment followed by topical sirolimus application after Er:Yag laser ablation of the stratum corneum compared with 2) PDL treatment followed by topical sirolimus application without Er:Yag laser ablation of the stratum corneum, 3) PDL treatment only and 4) sirolimus application only. After the six months follow-up period, during the second treatment period, patients will receive an additional five treatments of the adjacent cosmetic unit of the treated part of the PWS, employing the most successful of the four treatment modalities as evaluated after the first treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sirolimus | sirolimus (40 µl) will be applied under occlusion, using van der Bend patch-test chambers (size: 1cm2), and left in situ for 7 days. |
| OTHER | Erbium yag laser | Er:Yag laser ablation of the stratum corneum |
| DEVICE | Pulsed Dye Laser |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2016-01-01
- Completion
- 2016-12-01
- First posted
- 2014-08-12
- Last updated
- 2017-02-08
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02214706. Inclusion in this directory is not an endorsement.